Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Imjudo (tremelimumab) is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab, and for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations in combination with durvalumab and platinum-based chemotherapy.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• The combination of durvalumab and tremelimumab demonstrated statistically significant improvements in overall survival, response rates, and progression-free survival in patients with advanced hepatocellular carcinoma (HCC) compared to sorafenib, positioning it as a new standard of care.
• In patients with extensive-stage small cell lung cancer (ES-SCLC), the durvalumab-tremelimumab combination was not highlighted as superior in overall survival (OS) or progression-free survival (PFS) when compared to other regimens, specifically serplulimab, which outperformed durvalumab-tremelimumab in these metrics.
• No specific differences in effectiveness were noted among various population types or subgroups in the provided evidence.
• In a population treated with durvalumab-tremelimumab, 77.8% experienced any adverse events (AEs), 29.3% experienced grade ≥ 3 AEs, 34.9% experienced serious AEs, and 13.3% discontinued treatment due to AEs. The treatment-related mortality rate was 0.98%, with common AEs being fatigue (30.1%), diarrhea (21.7%), pruritus (17.9%), decreased appetite (17.7%), and nausea (15.6%).
• No significant safety differences were observed between first-line and second-line or later treatments, and no specific safety concerns or adverse effects were noted for particular population types or subgroups.